Regeneron Pharmaceuticals has received US$450 million through Operation Warp Speed to make and supply its coronavirus vaccine candidate, REGN-COV2. REGN-COV2 is currently in two Phase 2/3 clinical trials for the treatment of the coronavirus and in a Phase 3 trial for the prevention of virus infection. — LabCorp is launching an at home virus test collection service. LabCorp then delivers the patient’s test results to the healthcare provider’s electronic medical record and the patient’s LabCorp Patient Portal. The service received Emergency Use Authorization by the FDA on July 1.--AP

Source: The Standard July 07, 2020 15:11 UTC